I mean, how do I see if two reads come from the same sample? The manual only tells me that 2 reads having identical QNAME are paired-end, right? Could someone tell how to read QNAME, above all it's such a long string of words that must tell something other than that...
-
-
I just wanted to know if there's barcode for sample information (in cases of pooled sample), where would it be? Thx~~ -
What manual?Comment
-
Often the QNAME is info about the instrument and the date of run, and the lane and tile and xy coordinates. The read group might tell you the sample name. That might be stored in an NM tag in the .sam file, or in the @RG header of the .sam fileComment
-
The NM tag is for the # of mismatches. Look in the RG header, if present.Originally posted by swbarnes2 View PostComment
-
-
Right, typo on my part. The SM tag might contain a sample name.Originally posted by nilshomer View PostComment
-
Well, the description for the SM tag is"SM:Sample. Use pool name where a pool is being sequenced." I wasn''t putting it clearly...what I meant was, if this sample is pooled, and the origins of the sample content each is barcoded, is it possible that this infomation is contained in .SAM format? And this must be contained in the non-header sectoin...Originally posted by swbarnes2 View Post
If it is not, how is that usually done? Is it customary that I ligate an adaptor to each sample origin, pool them, sequence, and look at the beginning of each read to see which origin of sample it came from?
Lots of thx!!!Comment
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM -
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM
Comment